Assessing the relative efficacy of new drugs: An emerging opportunity

Nature Reviews Drug Discovery

Volumn 14, Issue 7, 2015, Pages 443-444

  Eichler, Hans Georg ^a   Thomson, Andrew ^a   Eichler, Irmgard ^a   Schneeweiss, Sebastian ^b  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; CANAGLIFLOZIN; NEW DRUG; ROFECOXIB;

CHRONIC DISEASE; DISEASE REGISTRY; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; GOLD STANDARD; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELATIVE EFFICACY; REVIEW; STUDY DESIGN; ANIMAL; ATRIAL FIBRILLATION; COST BENEFIT ANALYSIS; ECONOMICS; TREATMENT OUTCOME; TRENDS;

ANIMALS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; DRUGS, INVESTIGATIONAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84934283088     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4664     Document Type: Review

References (5)

1. Bombardier, C. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343, 1520-1528 (2000).
2. EUnetHTA WP5 Joint Action 2 Strand A. Rapid Relative Effectiveness Assessment of pharmaceuticals. Pilot assessment using the HTA Core Model® for rapid relative effectiveness assessment: canagliflozin for the treatment of type 2 diabetes mellitus [online], http://www.eunethta.eu/sites/5026.fedimbo. belgium.be/files/WP5-SA-2-canagliflozin-for-the-treatment-of-diabetes-mellitus.pdf
3. Schneeweiss S. et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes 5, 480-486 (2012).
4. Strom, B. et al. Data sharing, year 1-access to data from industry-sponsored clinical trials. N. Engl. J. Med. 371, 2052-2054 (2014).
5. Keener, A, B. Group seeks standardisation for what clinical trials must measure. Nature Med. 20, 798-799 (2014).